# A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based

Source: https://onco.cc/trials/nct07803783/  
OnCo record `nct07803783` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of YL201, liposomal irinotecan, fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., not yet recruiting.

## Summary

A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy is a phase 3, randomised interventional study registered as NCT07803783 by MediLink Therapeutics (Suzhou) Co., Ltd., with a registry enrolment figure of 320 participants, started 2026-10 and due to reach its primary completion in 2029-01. Interventions recorded: Tambotatug pelitecan; Liposomal irinotecan; 5 Fluorouracil; Leucovorin. Conditions listed: Metastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: PFS by BICR; OS. Pancreatic eligibility wording from the registry: "Participants must have histologically or cytologically confirmed incurable metastatic pancreatic ductal adenocarcinoma (PDAC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07803783
- Phase: 3
- Setting: A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT07803783: https://clinicaltrials.gov/study/NCT07803783

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [YL201](https://onco.cc/drugs/yl201/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07803783.json